Abaloparatide TFA

• CAT Number: I046105
• Molecular Formula: C176H301N56F3O51
• Molecular Weight: 4074.61
• Purity: ≥95%

Abaloparatide TFA (BA 058 TFA) is a parathyroid hormone receptor 1 (PTHR1) analogue. Abaloparatide TFA also is a selective PTHR1 activator. Abaloparatide TFA enhances Gs/cAMP signaling and β-arrestin recruitment. Abaloparatide TFA enhances bone formation and cortical structure in mice. Abaloparatide TFA has the potential for the research of osteoporosis[1][2].
Abaloparatide TFA (0-100 nM; 40 min) enhances Gs/cAMP signaling and β-arrestin recruitment in MC3T3-E1 cells[1].
Abaloparatide TFA (0-100 nM) efficiently induces PTHR1 internalization in a dose-dependen manner with an EC50 value of 0.8 nM in U2OS Cell[1].
Abaloparatide TFA (20-80 µg/kg; s.c.; daily for 30 days) enhances bone formation and cortical structure in mouse[1].

Reference

[1]. Sahbani K, et al. Abaloparatide exhibits greater osteoanabolic response and higher cAMP stimulation and β-arrestin recruitment than teriparatide. Physiol Rep. 2019 Oct;7(19):e14225.
 [Content Brief]

[2]. Varela A, et al. One Year of Abaloparatide, a Selective Activator of the PTH1 Receptor, Increased Bone Formation and Bone Mass in Osteopenic Ovariectomized Rats Without Increasing Bone Resorption. J Bone Miner Res. 2017 Jan;32(1):24-33.
 [Content Brief]